CN114807032A - Application of dexamethasone in preparation of anti-inflammatory drugs for inducing extracellular vesicles produced by neutrophils - Google Patents
Application of dexamethasone in preparation of anti-inflammatory drugs for inducing extracellular vesicles produced by neutrophils Download PDFInfo
- Publication number
- CN114807032A CN114807032A CN202210548483.3A CN202210548483A CN114807032A CN 114807032 A CN114807032 A CN 114807032A CN 202210548483 A CN202210548483 A CN 202210548483A CN 114807032 A CN114807032 A CN 114807032A
- Authority
- CN
- China
- Prior art keywords
- dexamethasone
- neutrophil
- vesicles
- neutrophils
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000440 neutrophil Anatomy 0.000 title claims abstract description 32
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title claims abstract description 23
- 229960003957 dexamethasone Drugs 0.000 title claims abstract description 23
- 230000001939 inductive effect Effects 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 229940124599 anti-inflammatory drug Drugs 0.000 title abstract description 3
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 230000002792 vascular Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 4
- 230000003511 endothelial effect Effects 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000001976 improved effect Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 24
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102000000018 Chemokine CCL2 Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/231—Interleukin-10 (IL-10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of dexamethasone in inducing neutrophil to generate extracellular vesicles. Also discloses application of the dexamethasone to preparation of anti-inflammatory drugs for inducing the extracellular vesicles produced by the neutrophils. Dexamethasone stimulation can lead the expression level of anti-inflammatory factors IL-10 and TGF-beta in the neutrophils to be obviously up-regulated; and after the neutrophil granulocytes are stimulated by dexamethasone, the vesicle preparation yield is at least 10 times higher than that of an untreated neutrophil group. Therefore, dexamethasone has the effect of promoting the secretion of vesicles from the neutrophil, and the vesicles generated by the neutrophil are stimulated by the dexamethasone, so that the content of IL-10 and TGF-beta is remarkably improved, the dexamethasone has better vascular endothelial adhesion capability and anti-inflammatory activity, is expected to be developed into a novel biological treatment technology, and can be used for treating clinically refractory inflammatory related diseases.
Description
Technical Field
The invention relates to application of dexamethasone to preparation of a medicine for treating inflammation, wherein the dexamethasone induces extracellular vesicles produced by neutrophils.
Background
Extracellular Vesicles (EVs) are nanoscale Vesicles secreted by cells and have membrane structures, can carry various biomolecules such as proteins, lipids, miRNA, lncRNA and DNA, and can effectively protect the activity of corresponding biomolecules due to the closed membrane structure. Meanwhile, EVs can inherit the receptors and ligands of parent cells, and due to the nanometer-scale size of the EVs, the EVs are beneficial to crossing various physiological barriers in vivo and can be enriched in specific organ and tissue cells. Therefore, the extracellular vesicles can regulate the functions of target cells through the encapsulated biomolecules and are an important intercellular communication mode. In addition, as a natural biological vesicle, EVs also has the advantages of low toxicity, low immunogenicity, good biocompatibility and the like, so that the biological therapy based on the extracellular vesicle has good clinical application prospect.
Neutrophils, which are an important immune cell population in the body, play an important role in inflammation-related diseases and defense against pathogen infection because of their strong chemotaxis and ability to reach the focal site across vascular endothelial cells in early onset. The migration of neutrophils across the blood vessel to the lesion site requires first the vascular endothelial cells that adhere to the lesion site, followed by cell deformation out of the vessel to the site of the inflamed tissue. The neutrophil-derived extracellular vesicle can inherit the property of a neutrophil membrane, for example, the surface of the neutrophil-derived extracellular vesicle is also rich in Integrin beta 2, which suggests that the neutrophil-derived extracellular vesicle also has better targeting performance for inflammatory tissues. However, the preparation efficiency of extracellular vesicles is always a key factor limiting the large-scale application of the extracellular vesicles. Therefore, it is very important to find a new stimulant which can effectively improve the production efficiency of the vesicle while ensuring the vesicle to inherit the characteristics of the parent cell.
Disclosure of Invention
The invention aims to provide application of dexamethasone in inducing neutrophil to generate extracellular vesicles.
Another objective of the invention is to provide the application of dexamethasone to the preparation of the medicine for treating inflammation diminishing, wherein the dexamethasone induces the extracellular vesicles produced by the neutrophils.
Has the advantages that: dexamethasone stimulation can lead the expression level of anti-inflammatory factors IL-10 and TGF-beta in the neutrophils to be obviously up-regulated; and after the neutrophil granulocytes are stimulated by dexamethasone, the vesicle preparation yield is at least 10 times higher than that of an untreated neutrophil group. Therefore, dexamethasone has the effect of promoting the secretion of vesicles from the neutrophil, and the vesicles generated by the neutrophil are stimulated by the dexamethasone, so that the content of IL-10 and TGF-beta is remarkably improved, the dexamethasone has better vascular endothelial adhesion capability and anti-inflammatory activity, is expected to be developed into a novel biological treatment technology, and can be used for treating clinically refractory inflammatory related diseases.
Drawings
FIG. 1 is a transmission electron microscope analysis view of neutrophil-derived extracellular vesicles.
FIG. 2 is a diagram of Nanoparticle Tracking Analysis (NTA) analysis of neutrophil-derived extracellular vesicles.
FIG. 3, the vascular endothelial adhesion ability of the vesicles was examined in vitro.
FIG. 4, in vitro evaluation of the anti-inflammatory effect of the vesicles on vascular endothelial cells.
Figure 5, in vitro evaluation of the anti-inflammatory activity of the vesicles on macrophages (qRT-PCR).
Figure 6, in vitro evaluation of the anti-inflammatory activity (ELISA) of the vesicles on macrophages.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. These examples are intended to illustrate the invention and are not intended to limit the scope of the invention.
A method of isolating extracellular vesicles from dexamethasone-induced neutrophils, comprising the steps of:
1) dexamethasone stimulated neutrophils for two days;
2) centrifuging the cells at room temperature of 300g for 5min, and removing the cells;
3) taking the supernatant, centrifuging at room temperature of 2000g for 10min, and removing cell debris;
4) taking the supernatant, centrifuging at 160000g for 1h at 4 ℃, and obtaining the extracellular vesicles from white micro flocculent precipitates at the bottom of a centrifuge tube.
S1, characterizing morphological features of the above-obtained neutrophil-derived extracellular vesicles, and analyzing morphology and particle size of the vesicles by Transmission Electron Microscopy (TEM) (see fig. 1) and Nanoparticle Tracking Analysis (NTA) (see fig. 2).
S2, detecting the vascular endothelial adhesion capability of the vesicle. Firstly, culturing a monolayer of human umbilical vein endothelial cells HUVEC in a pore plate, activating the cells by using LPS, and then fixing the cell morphology; the adhesion of the DiI dye-labeled vesicles to the immobilized HUVEC cells was observed by immunofluorescence after incubation for 6h or 12 h. The experimental results demonstrate that the significant increase of ICAM-1 expression on the surface of HUVEC cells after activation by LPS stimulation will help the neutrophil-derived vesicles to adhere to vascular endothelial cells, so that more vesicles can be observed to adhere to LPS-activated cells compared to normal umbilical vein endothelial cells, and the amount of vesicles adhering to the surface of activated HUVEC cells gradually accumulates as the incubation time is prolonged (see fig. 3). Relevant results show that the separated vesicle from the neutrophil has stronger vascular adhesion capability and can be more effectively adhered to vascular endothelial cells in an inflammatory state, which is particularly important for the subsequent targeting and enrichment of EVs at inflammatory sites.
S3, the inflammation inhibition effect of EVs on HUVEC cells activated by LPS is also determined while the vesicle vascular adhesion capability is detected. And (3) incubating NC-EVs and Dex-EVs with the activated cells for 24h, and collecting cells to detect the expression condition of related genes. The experimental result shows that the expression of inflammatory factors is up-regulated after LPS activation, such as IL-1 beta, IL-6, TNF-alpha, monocyte chemotactic protein 1 (MCP-1) and the like, wherein the MCP-1 gene is obviously increased by about 12 times. Meanwhile, compared with NC-EVs, Dex-EVs have obvious inflammation inhibition effect on activated HUVEC cells and obviously reduce the level of relevant proinflammatory factors (figure 4).
S4, the anti-inflammatory effect of EVs on LPS-activated Raw264.7 cells was evaluated by qRT-PCR and ELISA assays. The inflammation inhibition effect of Dex-EVs on activated macrophages is evaluated from the mRNA level of the gene, and the result shows that the mRNA level of IL-10 is up-regulated to about 20 times of that of a Control group after the Dex-EVs are absorbed by macrophages activated by LPS, and meanwhile, the expression levels of proinflammatory factors such as IL-1 beta, IL-6, TNF-alpha and the like are obviously down-regulated (figure 5); the secretion of inflammatory cytokines in the culture supernatant of Raw264.7 cells is also detected, and the result is shown in the figure, the content of the proinflammatory mediators in the cell supernatant taking Dex-EVs is obviously reduced, and the IL-10 secretion is greatly improved to about 4000pg/ml, which is critical for the subsequent Raw264.7 cells to exert anti-inflammatory activity and even eliminate inflammatory response (figure 6). In contrast, the levels of inflammatory factors were not significantly different after Raw264.7 cells phagocytosed NC-EVs compared to LPS alone treated groups.
Claims (2)
1. Use of dexamethasone for inducing neutrophil production of extracellular vesicles.
2. Application of dexamethasone in preparing medicine for treating inflammation and inducing extracellular vesicle generated by neutrophil is provided.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210548483.3A CN114807032B (en) | 2022-05-20 | 2022-05-20 | Application of dexamethasone-induced neutrophil-produced extracellular vesicles in preparation of anti-inflammatory drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210548483.3A CN114807032B (en) | 2022-05-20 | 2022-05-20 | Application of dexamethasone-induced neutrophil-produced extracellular vesicles in preparation of anti-inflammatory drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114807032A true CN114807032A (en) | 2022-07-29 |
CN114807032B CN114807032B (en) | 2023-09-12 |
Family
ID=82514773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210548483.3A Active CN114807032B (en) | 2022-05-20 | 2022-05-20 | Application of dexamethasone-induced neutrophil-produced extracellular vesicles in preparation of anti-inflammatory drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114807032B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5300292A (en) * | 1991-05-03 | 1994-04-05 | The Regents Of The University Of California | Composition and method for treating inflammation |
US20050089523A1 (en) * | 1998-07-13 | 2005-04-28 | Board Of Regents, The University Of Texas System | Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids |
CN102373175A (en) * | 2010-08-20 | 2012-03-14 | 南京大学 | Application of raloxifene in mesenchymal stem cell in-vitro osteoblast differentiation |
US20160199509A1 (en) * | 1998-07-13 | 2016-07-14 | Board Of Regents, The University Of Texas System | Cancer Treatment Comprising Therapeutics That Bind to Phosphatidylserine |
CN106177959A (en) * | 2016-04-01 | 2016-12-07 | 北京大学 | Anti-cancer composition and preparation thereof and application |
CN108350022A (en) * | 2015-11-12 | 2018-07-31 | 内布拉斯加大学董事会 | Conjugated glucocorticoid pro-drug of polyethylene glycol and combinations thereof and method |
CN108619114A (en) * | 2018-05-02 | 2018-10-09 | 东南大学 | A kind of Macrophage derived microcapsule bubble and its preparation method and application of load dexamethasone |
CN111148531A (en) * | 2017-09-08 | 2020-05-12 | 伊夫罗生物科学公司 | Bacterial extracellular vesicles |
KR20200113838A (en) * | 2019-03-26 | 2020-10-07 | 인천대학교 산학협력단 | A method for regulation of angiogenesis cytokine in stem cell-derived extracellular vesicles by using mechanical stiffness of hydrogel |
CN113827738A (en) * | 2020-06-08 | 2021-12-24 | 沈阳药科大学 | Sialic acid modified dexamethasone palmitate liposome and preparation and application thereof |
CN114099481A (en) * | 2022-01-28 | 2022-03-01 | 深圳湾实验室 | Atomizing inhalation type glucocorticoid nano-drug and preparation method and application thereof |
-
2022
- 2022-05-20 CN CN202210548483.3A patent/CN114807032B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5300292A (en) * | 1991-05-03 | 1994-04-05 | The Regents Of The University Of California | Composition and method for treating inflammation |
US20050089523A1 (en) * | 1998-07-13 | 2005-04-28 | Board Of Regents, The University Of Texas System | Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids |
US20160199509A1 (en) * | 1998-07-13 | 2016-07-14 | Board Of Regents, The University Of Texas System | Cancer Treatment Comprising Therapeutics That Bind to Phosphatidylserine |
CN102373175A (en) * | 2010-08-20 | 2012-03-14 | 南京大学 | Application of raloxifene in mesenchymal stem cell in-vitro osteoblast differentiation |
CN108350022A (en) * | 2015-11-12 | 2018-07-31 | 内布拉斯加大学董事会 | Conjugated glucocorticoid pro-drug of polyethylene glycol and combinations thereof and method |
CN106177959A (en) * | 2016-04-01 | 2016-12-07 | 北京大学 | Anti-cancer composition and preparation thereof and application |
CN111148531A (en) * | 2017-09-08 | 2020-05-12 | 伊夫罗生物科学公司 | Bacterial extracellular vesicles |
CN108619114A (en) * | 2018-05-02 | 2018-10-09 | 东南大学 | A kind of Macrophage derived microcapsule bubble and its preparation method and application of load dexamethasone |
KR20200113838A (en) * | 2019-03-26 | 2020-10-07 | 인천대학교 산학협력단 | A method for regulation of angiogenesis cytokine in stem cell-derived extracellular vesicles by using mechanical stiffness of hydrogel |
CN113827738A (en) * | 2020-06-08 | 2021-12-24 | 沈阳药科大学 | Sialic acid modified dexamethasone palmitate liposome and preparation and application thereof |
CN114099481A (en) * | 2022-01-28 | 2022-03-01 | 深圳湾实验室 | Atomizing inhalation type glucocorticoid nano-drug and preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
GYEONGYUN GO等: "Extracellular vesicle-mimertic ghost nanovesicles for delivering anti-inflammatory drugs to mitigate gram-negative bacterial outer membrane vesicle-induced systemic inflammatory response syndrome", ADV HEATHC MATER * |
张赶: "***靶向的仿生REMV在***炎及肿瘤***转移中的应用研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑 * |
Also Published As
Publication number | Publication date |
---|---|
CN114807032B (en) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103232973B (en) | A kind of K562 cell amplification activates the method for NK cell | |
CN107988153A (en) | The method of mesenchymal stem cells derived from human umbilical blood source separation excretion body and the reagent used | |
CN105779386B (en) | A kind of application of mescenchymal stem cell in preparation treatment M5 type leukemia medicament | |
CN108753682B (en) | Promote endothelial cell into the excretion body active ingredient and its preparation method and application of blood vessel | |
CN109925516A (en) | A kind of composite hydrogel and preparation method thereof loading excretion body | |
CN110777142A (en) | Method for promoting secretion of extracellular fluid by low-intensity pulse ultrasonic stimulation | |
CN112111424A (en) | Bifidobacterium breve capable of relieving rheumatoid arthritis and application thereof | |
CN110075124A (en) | AMSC-MALAT1-Exo is used to prepare application in the drug for the treatment of liver diseases and preparation method thereof | |
CN111944748A (en) | high-IL-10-expression human adipose-derived mesenchymal stem cell exosome for treating myocardial infarction and application thereof | |
CN114874981A (en) | Mesenchymal stem cell exosome and application thereof in immune cell culture | |
CN102191219A (en) | Method for preparing cytokine-induced killer (CIK) cells with high efficiency | |
CN114807032B (en) | Application of dexamethasone-induced neutrophil-produced extracellular vesicles in preparation of anti-inflammatory drugs | |
CN106011074B (en) | Mesenchymal stem cell with high expression of CXCR5 and preparation and application thereof | |
CN112675203A (en) | Application of cell-derived exosome in preparation of biological preparation for treating asthma and/or pulmonary fibrosis | |
CN106267413B (en) | AIDS plasma purification device | |
CN1746297A (en) | Placenta derived mesenchymal stem cell and preparation thereof | |
CN103558392B (en) | A kind of effect of the antiatherosclerotic based on inflammatory reaction evaluation method | |
CN115671136A (en) | Application of M0 or M1 type Ly6C + CX3CR1+ monocyte-derived macrophage in treating hepatic fibrosis | |
JP2020533981A (en) | Mesenchymal stem cells overexpressing CXCR5, their production methods and uses | |
CN115478048A (en) | Preparation of exosome by culturing adipose-derived mesenchymal stem cells | |
CN112626017B (en) | Preparation method and application of NK cell exosome | |
CN115645408A (en) | Drug for improving myocardial hypertrophy and cardiac fibrosis by targeting MrgD | |
CN112029705B (en) | Method for promoting endothelial cells to produce exosomes, exosome preparation and application | |
KR20150020112A (en) | Mesenchymal stem cells treated metformin having immuno-modulating activity and cell therapeutic agent for preventing or treating immune disease | |
CN103040867A (en) | Application of microvesicles from bone marrow mesenchymal stem cells in preparing drug for treating kidney injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |